Skip to main content

Our industries

Healthcare and pharmaceutical

We are recognised as a leading advisor for patent prosecution and litigation, corporate and licensing work in the healthcare and pharmaceutical sectors.

Our team stays up-to-date with the rapidly changing landscape of these innovative sectors, advising research institutions, healthcare providers, medical device companies and major pharmaceutical players on the full spectrum of their legal concerns, including regulatory issues such as product registration, clinical trial regulation and marketing authorization applications.

Our IP expertise is designed to protect all aspects of our clients’ portfolios. We advise on one-off filings, prosecution and litigation, and assist with all aspects our clients’ IP strategies. Our expertise encompasses the full range of patents, trade marks and copyrights. Our clients are major international household names with diverse IP portfolios, and leading local clients with strong brands nationally and in the region.

We handle broad range of healthcare related advisory work, including compliance, risk management and related dispute resolution.

Practice areas
  • Drugs manufacturing and distribution
  • Product licensing
  • Regulatory compliance
  • Commercial
At a glance
  • Novartis Pharma Pakistan Limited: represented client in suits and thereafter appeals filed by ex-employees before the District Courts and thereafter the High Court of Sindh bench at Larkana.
  • Pakistan Chemists and Druggists Association: represented client and obtained an interim order restraining the operation of section 7 of the import pricing policy as issued by the Drug Regulatory Authority of Pakistan on behalf of the Defending American Life Insurance Company (Pakistan) Limited (ALICO Pakistan) (now known as IGI Life Insurance Limited) and American Life Insurance Company (ALICO) in two suits filed before the High Court of Sindh at Karachi by employees of American Life Insurance Company (Pakistan) Limited, against the intended sale of ALICO’s majority shareholding in ALICO Pakistan, to IGI Insurance Limited.
  • Pfizer Corporation: represented client in the re-structuring and merger of its subsidiaries in Pakistan.
  • Searle IV Solutions: represented client, one of the leading pharmaceutical companies of Pakistan manufacturing lifesaving IV solutions, in a suit relating to whether an S.R.O granting a tax exemption applied to the material imported by Searle.

Stay in touch

Subscribe to our newsletter

Stay in touch
Sending

News/Insight

  • Lexology Getting The Deal Through – Private Equity (Fund Formation) 2021
    Private Equity (Fund Formation) 2021: United Arab Emirates (Published in April 2021)


    Read more
  • Lexology Getting The Deal Through – Private Equity (Transactions) 2021
    Private Equity (Transactions) 2021: United Arab Emirates (Published in April 2021)


    Read more
  • LexisNexis Foreign Investment Law Guide 外国投资法指南 2018–2019
    For an update on foreign investment practices around the world with an Asia-Pacific focus, please review the LexisNexis Foreign Investment Law Guide 2018 -2019 eBook


    Read more
  • DFSA enhances its Collective Investment Funds Regime
    Following the consultation period on a number of proposed legislative changes that were set out in Consultation Paper No. 115, the DFSA has made amendments to the Collective Investment Law 2010 and the DFSA Rulebook.


    Read more
  • LexisNexis Mergers & Acquisitions Guide 2019
    The sixth annual complimentary guide to understanding M&A practices around the world with an Asia-Pacific focus.


    Read more

What they say...

  • Global Law Experts Recommended Firm 2017

  • Chambers Asia Pacific 2016

  • Legal 500 Leading Firm 2015

  • IFLR1000 Financial & Corporate Top Tier Law Firm 2015

  • Chambers Asia Pacific 2015

Read more